Danaher Corporation

- No explicit mention of new fundraising through debt or equity in the provided transcript. - Post-Masimo deal, the company expects a net debt leverage of about 2.5 turns. - Strong free cash flow generation of over $5 billion per year and EBITDA support rapid deleveraging. - The company feels well-positioned with a strong balance sheet for further capital deployment, including M&A. - No indication of plans to raise equity; focus is on using existing balance sheet capacity and cash flow. - Overall readiness to pursue acquisitions using current financial resources without needing new fundraising.

- Danaher is accelerating growth investments, moving some from the second half of the year into Q2 to capitalize on opportunities. - There is notable investment activity in bioprocessing equipment, supported by more than 30% year-over-year order growth, driven by underinvestment in capacity and new biosimilars and compounds entering the market. - Brownfield and greenfield investments are underway, including equipment capacity expansions and reshoring-related projects, with some orders already placed for brownfield expansions. - The company is enhancing its portfolio via strategic M&A, highlighted by the pending acquisition of Masimo, expected to close later this year. - Investments are also reflected in new product introductions and strategic partnerships, such as Cytiva's advanced mRNA purification platform and Beckman Coulter Life Sciences' partnership with Automata for AI-driven tools. - Overall, Danaher emphasizes continual capital deployment backed by strong free cash flow and a robust balance sheet.

- Full-year 2026 core revenue growth guidance remains at 3% to 6%, with low single-digit growth expected in Q2 and acceleration through the year. - Headwinds from China diagnostics, respiratory, and life sciences comps (~300 basis points) are expected to abate by year-end, enabling mid-single-digit core growth exit in Q4. - Encouraged by early 2026 momentum: Life Sciences and Biotechnology businesses in China accelerating; bioprocessing consumables showing consistent high single-digit growth; equipment orders improving with over 30% YoY increase. - Equipment orders growth in bioprocessing expected to support growth beyond 2026, though 2026 guide assumes flat equipment revenue. - Masimo acquisition expected to be accretive to adjusted diluted net earnings in the first full year post-acquisition and deliver high single-digit return by year five. - AI is anticipated to accelerate pharma development, leading to increased demand for Life Science and Bioprocessing solutions.

- Danaher expects mid- to high single-digit earnings growth in H1 2026, putting them on track for the full year. (Page 7) - Full-year 2026 adjusted diluted EPS guidance was raised slightly to a range of $8.35 to $8.55, up from $8.35 to $8.50 previously. (Page 4) - The company plans for low single-digit core revenue growth in Q2 2026, with a sequential improvement from Q1. (Page 4) - Core growth guidance for full-year 2026 remains 3% to 6%. (Page 4) - Headwinds impacting growth (~300 basis points) expected to abate by year-end, supporting acceleration to mid-single-digit revenue growth exiting Q4. (Pages 4, 11, 12) - High single-digit growth in bioprocessing consumables expected to continue, with equipment growth possibly accelerating beyond flat guidance. (Page 5, 7) - The respiratory segment expects a return to an endemic revenue rate (~$1.8 billion) by Q4, benefiting overall results. (Page 12)

- Bioprocessing equipment orders showed over 30% year-over-year growth in Q1, coming off a lower base the previous year. - The first quarter orders growth was the first positive year-over-year growth in nearly 2 years. - Sequentially, Q1 orders were slightly down quarter-over-quarter due to typical seasonality. - Equipment order book trends are supported by robust funnel activity and larger order sizes. - Orders growth driven by two factors: underinvestment in capacity (brownfield and greenfield investments) and reshoring dynamics. - Equipment orders assumed to be flat for the full year 2026, with positive indicators for future growth beyond 2026. - Customer readiness may cause lumpiness in equipment revenue recognition. - In Diagnostics, good momentum with solid funnel activity outside China. - Life Sciences shows improving funnel activity and stable or improving demand across segments.